Evidence map›Paper›PMID 32161146›Full record

ArticlemSphere2020

Nonclonal Emergence of Colistin Resistance Associated with Mutations in the BasRS Two-Component System in Escherichia coli Bloodstream Isolates.

Axel B Janssen, Toby L Bartholomew, Natalia P Marciszewska, Marc J M Bonten, Rob J L Willems, Jose A Bengoechea, Willem van Schaik

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 44 citations in OpenAlex.

  1. Increased Prevalence of Multidrug-ResistantLife (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A review of colistin-resistantArchives of Razi Institute · 2024
    Review
  7. Article
  8. Article
  9. Genome-Wide Analysis of Innate Susceptibility Mechanisms ofAntibiotics (Basel, Switzerland) · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Colistin resistance inMicrobiology (Reading, England) · 2021
    Article
  15. Article
  16. A Resistance Mechanism in Non-Microbiology spectrum · 2021
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Axel B JanssenDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Toby L BartholomewWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Natalia P MarciszewskaDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Marc J M BontenDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Rob J L WillemsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Jose A BengoecheaWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Willem van SchaikDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands w.vanschaik@bham.ac.uk.
Utrecht University · NLQueen's University Belfast · GBUniversity Medical Center Utrecht · NL

Funding

Biotechnology and Biological Sciences Research Council BB/P020194/1
6 · The paper itself

Abstract

Infections by multidrug-resistant Gram-negative bacteria are increasingly common, prompting the renewed interest in the use of colistin. Colistin specifically targets Gram-negative bacteria by interacting with the anionic lipid A moieties of lipopolysaccharides, leading to membrane destabilization and cell death. Here, we aimed to uncover the mechanisms of colistin resistance in nine colistin-resistant

Indexed as

Anti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsHumansMicrobial Sensitivity TestsMutationPhylogenySignal TransductionTertiary Care CentersWhole Genome SequencingAnti-Bacterial AgentsColistinEscherichia coli Proteinsantibiotic resistancecolistinEscherichia colitwo-component regulatory systemswhole-genome sequencing

Identifiers

PMID32161146
PMCPMC7067592
OpenAlexW3011896977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.